Navigation Links
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
Date:11/5/2013

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology™-based production process that has been developed at Pfenex, through its vaccines division.  Funding will be provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).

"We are pleased to award this contract to Paragon Bioservices," stated Bertrand C. Liang, Chief Executive Officer. "This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase 1 clinical trial."

Marco A. Chacon, Ph.D., CEO of Paragon stated, "My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons."

About Pfenex Inc.

Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs. Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division. For more information please visit www.pfenex.com  

About Paragon Bioservices Inc.

Founded in 1990, Paragon Bioservices is a contract research and manufacturing organization whose focus is the production of reagent-grade proteins and biopharmaceuticals for clinical use. Areas of expertise include: Vaccines, VLP technologies, therapeutic proteins, monoclonal antibodies and viral vectors. The cGMP manufacturing space includes microbial and mammalian suites, fill-finish, and fully-segregated Virus/BSL-3 facilities.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
3. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
4. Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
8. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
10. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
11. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):